19 February 2014Gabriel di Blasi

Tackling the patent backlog in Brazil

The Brazilian Patent Office (INPI) has been facing a huge backlog of patent applications, which has led to an average waiting time for examination of about 10 years, an extremely long period compared with other countries. The delays apply for both patent and utility model (UM) applications, with the examination of UM applications being slightly less, around eight years.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

10x and Parse set to end sequencing feud after appeals court defeat

23 October 2026 Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.

Pharma

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends

22 October 2026 Questions over what Boehringer’s patents actually proved dominated the final day of the hearing, but a push for a further finding raised the stakes, with a possible appeal threatening to keep Dr Reddy’s off the market even if it won.

Pharma

Amarin and Hikma call time on six-year skinny label fight

22 October 2026 Following a major US Supreme Court win for generics, the landmark dispute has finally come to an end. A new filing brings closure to a case that raised questions over skinny labelling and induced patent infringement.

More features

Brazilian firm appoints patent strategist to lead department

Beyond the primary patent: How pharma can build competitive barriers

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

The UPC plugs another gap in its procedural rulebook

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

Patent office fee increases: What applicants must know

IndiaMart v CDSCO: A test of intermediary liability

Part I: Ozempic goes generic as Novo’s key patent expires

Tackling the patent backlog in Brazil

More on this story

Editor's picks

Editor's picks

More features